Quantum Biopharma (QNTM) Cash from Investing Activities (2020 - 2026)

Quantum Biopharma has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$2.9 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$2.9 million, down 114.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.6 million (down 122.49% YoY), and the FY2025 annual result was -$2.0 million, down 29.86% from the prior year.
• Cash from Investing Activities came in at -$2.9 million for Q1 2026 at Quantum Biopharma, down from $350650.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $11.9 million in Q4 2022 to a low of -$2.9 million in Q1 2026.
• The 4-year median for Cash from Investing Activities is -$22140.0 (2024), against an average of $1.3 million.
• Peak annual rise in Cash from Investing Activities reached 71.81% in 2025, while the deepest fall reached 5998.5% in 2025.
• Quantum Biopharma's Cash from Investing Activities stood at $11.9 million in 2022, then tumbled by 89.55% to $1.2 million in 2024, then tumbled by 71.81% to $350650.0 in 2025, then plunged by 925.11% to -$2.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$2.9 million (Q1 2026), $350650.0 (Q4 2025), and -$1.4 million (Q1 2025), per Business Quant data.